Sentences with phrase «of pharma companies»

Results of tests, and later rollouts, affects stock prices of Pharma companies.

Much of the problem, Miller explained, is that Americans are already shouldering more than their fair share of pharmaceutical companies» costs: While the U.S, accounts for only 4.6 % of the total world population, it makes up about 40 % of the world's drug spending, and the bulk of pharma companies» profits, he said.

Add one more name to the new slew of pharma companies trying to counteract the public backlash to big drug price increases: France's Sanofi, a $ 126 billion firm known for its flagship diabetes and vaccines units.

To me it looks like a company that claims no value on its intellectual property which is HIGHLY unorthodox for what is essentially the core asset of any pharma company (no unusual if there is no actual value, which i suspect).

Not exact matches

In B.C. especially, companies such as QLT Inc., Angiotech Pharmaceuticals and Cardiome Pharma Corp. saw their valuations soar in the early 2000s, only to come crashing to earth by the end of the decade as a result of competitive pressures, regulatory snags, strategic blunders and deals gone awry.

Danish pharma company Novo Nordisk (nvo), best known for its insulin - based treatments for diabetes, said Tuesday it's going to shift its focus slightly to fighting obesity, one of the primary causes of that disease.

While the early - stage company still mounted losses for the quarter, it received more revenue than expected as a result of its collaboration with pharma giant Pfizer.

On average, the 30 large and small pharmaceutical and biotech companies IDEA Pharma examined got just 11 % of their 2017 revenue from drugs developed within the past five years, says Mike Rea, the firm's CEO and one of the most insightful people I've met — no exaggeration — when it comes to pinpointing innovation choke points in the drug industry.

Leslie Dan's latest company, Viventia Bio, looked all set for a robust 2015 and 2016 before a series of scandals at Valeant Pharmaceuticals brought Canada's whole biotech and pharma sector crashing down.

-- Ahmed Albaiti, founder and CEO of Medullan, a digital health innovation company that works with payers, providers, and pharma on patient engagement.

But the initiative comes with another huge financial prize for firms that successfully win FDA approval for these niche therapies: a priority review voucher that can be used to slash the regulatory period for a different experimental specialty treatment being developed by a drug maker or, more often, sold for potentially hundreds of millions of dollars to another pharma company.

Kite Pharma, one of the companies chasing a new generation of cancer drugs called chimeric antigen receptor T - cell (CAR - T) therapies, announced a patient death in a clinical trial of its experimental KTE - C19.

Big biotech and pharma companies are absolutely dependent on being able to successfully innovate by partnering with and acquiring disruptive startups because of the nature of the patent cliff in pharmaceuticals.

The company runs clinical studies on behalf of its multinational pharma clients in oncology, respiratory / infectious disease and central nervous system disorders.

At that price, he would collect $ 800 million, or $ 200 million a year over four years — making more than the CEOs of more than a dozen major pharma companies are likely to be paid, combined.

Others, such as consumer watchdog Public Citizen and the preventive medicine advocacy group Trust for America's Health (TFAH), had very different takes, arguing Cures mostly benefits pharma companies at the expense of other important public health initiatives.

Martin Shkreli, unaffectionately known as the «pharma bro» — and infamous for his decision to hike the list price of Daraprim, a drug used by HIV / AIDS and cancer patients to combat infections, by more than 5,000 % in 2015 under his former company Turing Pharmaceuticals — was convicted on three criminal securities fraud and conspiracy charges by a Brooklyn jury on Friday.

In periods of rising volatility, pharma companies are often especially vulnerable because of investors are paying big prices today for therapies expected to pay off over a long horizon.

«On Nasdaq, the main investors for biotech stocks are mainly U.S. funds, but, in Hong Kong, we can better tap Chinese and Asian investors as we are closer to them,» said Yang Dajun, chairman of Ascentage Pharma, a Chinese biotech company.

Trump appears to be simultaneously criticizing inversion mergers that shift drug companies» tax domiciles overseas, pharma's tactic of using manufacturing plants in European, Asian, and African countries, and high drug prices.

The «microbiome,» or the collection of organisms that reside within the human body (especially the gut), has become a big new interest area for a number of major pharma companies like Merck and smaller biotechs alike.

At an investment conference in May, Ackman explained that his long position in the pharma firm stemmed from his belief that Valeant's aggressive acquisition style — and the outsized returns it had so far produced — made the company akin to a younger version of Warren Buffett's Berkshire.

Fortune spoke with 25 - year pharmaceutical vet Ramona Sequeira, president of Takeda's U.S. business unit since 2015, on the challenges of adapting an international pharma company to the U.S. healthcare and reimbursement system and the firm's America - centric business plans.

President Donald Trump sat down with a host of major pharma company CEOs Tuesday morning to address pressing issues like high drug prices, the future of the FDA, and where treatments are produced.

Pharma is generally proud of its diversity: A few days before the Trump enacted the ban, J&J published on its website the story of employee Abdullah Al Hommada, who fled his native Syria for the Netherlands and now works at the company's Janssen division.

With few competitors on the market, the pharma company reportedly planned on even steeper hikes to the price, figuring that a combination of customers» insurance coverage and discounts the company provides to patients would offset the increases.

InGenesis» client portfolio includes approximately half of Fortune 500 companies and the nation's leading healthcare, pharma, and research entities.

The report points to a number of factors driving big pharma companies» struggles with netting strong returns, including a dearth of late - stage pipeline candidates and diversified product portfolios that aren't necessarily spreading risk.

Today, at 2 p.m. Eastern, the President will sign the 21st Century Cures Act — approved by the Senate on Dec. 7 by a vote of 94 - to - 5, overwhelmingly passed by the House the week before, and seemingly supported by every pharma company, medical institution, healthcare advocate and their mothers.

The latest pharma innovation report from Deloitte holds some pretty grim news for pharma: returns on R&D investments by large cap companies slid to a mere 3.7 % in 2016, down from the 10.1 % returns seen in 2010 (although the cost of bringing a drug to market is beginning to stabilize).

Say you're a pharma company with a key product which brings in about $ 1.49 billion in annual sales, or a little less than 10 % of your revenue stream.

Ten of these companies, our honorees, have matched or outperformed the median annual revenue or profit for their peers in pharma, biotech, or tech, as tracked by EY and Capital IQ.

Many of the recent Big Pharma deals and acquisition proposals have been motivated by the companies» desire to lower their tax rate by acquiring a foreign rival and moving their headquarters overseas in a process known as an inversion.

By printing multiple lung airways — or any other afflicted organ — from a human patient and testing drugs on them, pharma companies can bypass the ethically challenged practice of testing on animals and proceed to human clinical trials with greater confidence the drugs will actually work, according to Wadsworth.

Pharma company Valeant's shares dropped 75 % after a short seller accused it of using a pharmacy to artificially inflate its sales.

Consider also a company like Horizon Pharma (HZNP), a biopharmaceutical firm that has acquired three other pharma firms since September ofPharma (HZNP), a biopharmaceutical firm that has acquired three other pharma firms since September ofpharma firms since September of 2014.

Giddying merry - go - round of pharma deals continues as Israeli company creates the world's biggest maker of generics.

Biotech giant Gilead Sciences is beefing up its cancer drug portfolio with a $ 11.9 billion deal to buy Kite Pharma, a company focused on a groundbreaking new class of treatments that turns the body's own immune cells into targeted blood cancer killers.

The companies jockeying for a first - to - market advantage in the space have encountered plenty of twists and turns along the way — and it appears that pharma giant Novartis may well achieve its original goal of a pioneering FDA approval for its own experimental treatment.

The intense, full - day strategy sessions invariably ended with Cornelius getting a headache, he says — particularly when he sparred with executives in the company who clung to vestiges of big, fat pharma.

One day I came home from working at a big pharma company that had the same type of elevator as my condo building in Toronto.

At a moment when the world's fourth - largest pharmaceutical company by sales (Pfizer) is eagerly courting the world's ninth - largest (the very same AstraZeneca from which Bristol decoupled)-- offering, in late May, a monumental dowry of around $ 120 billion — one can be forgiven for not noticing the more substantive change that's sweeping the pharmaceutical industry: Big Pharma is getting smaller.

Insurers have been striking deals with pharma companies that will land them discounts on pricey drugs if those treatments don't demonstrably improve patients» health outcomes; hospitals are penalized if they have high rates of patient readmissions.

The environment for deals among specialty pharma companies like Jazz has heated up since the beginning of the year.

Jazz said in a filing that it did so in response to the overall takeover environment for pharma companies and in light of a patent litigation settlement that allows Hikma Pharmaceuticals to sell a generic version of Xyrem with Jazz receiving royalty payments on those sales.

Drug companies including Purdue Pharma LP and Johnson & Johnson have been fighting lawsuits by two California counties, the city of Chicago, four counties in New York and the state of Mississippi over their opioid marketing practices.

Immuno - oncolocy has been the focus of Big Pharma and biotechs alike, with companies such as Merck (mrk), Bristol - Myers Squibb (bmy), Pfizer (pfe), Roche / Genentech, Juno (juno), Kite Pharma (kite), Novartis (nvs), and countless others pouring massive investments into the space (the Loncar ETF contains almost all of these companies).

In 2017, according to Deloitte, the 12 largest bio - pharma companies got a mere 3.2 % return out of their drug - research arms.

This was most likely one of the reasons the FDA has rejected pharma companies» petitions for it twice, according to FierceBiotech.

In its first year of business, Sun Pharma generated more than $ 100,000 in sales, and in 1994 the company went public on the Bombay Stock Exchange.